[go: up one dir, main page]

PE20080985A1 - Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano - Google Patents

Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano

Info

Publication number
PE20080985A1
PE20080985A1 PE2007001164A PE2007001164A PE20080985A1 PE 20080985 A1 PE20080985 A1 PE 20080985A1 PE 2007001164 A PE2007001164 A PE 2007001164A PE 2007001164 A PE2007001164 A PE 2007001164A PE 20080985 A1 PE20080985 A1 PE 20080985A1
Authority
PE
Peru
Prior art keywords
biciclo
azonia
isoxazol
carbamoyl
octane
Prior art date
Application number
PE2007001164A
Other languages
English (en)
Inventor
Stephanie Monnier
Gerhard Muhrer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080985A1 publication Critical patent/PE20080985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN CRISTAL POLIMORFICO DE BROMURO DE (R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-(ISOXAZOL-3-IL-CARBAMOIL-METIL)-1-AZONIA-BICICLO-[2.2.2]-OCTANO, DESIGNADO COMO LA FORMA DEL CRISTAL T ALFA, CARACTERIZADA POR UN PUNTO DE FUSION 208ºC, CON LAS LINEAS DE DIFRACION (2 THETA EN GRADOS ANGULARES ± 0.2ºC) EN EL PATRON DE DIFRACCION DE RAYOS X DE: 5.7º, 15.7º, 18.5º, 19.8º, 21.1º, 22.2º Y 24.0º. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA ADMINISTRACION TOPICA O EN AEROSOL CON UN DIAMETRO DE PARTICULA DE HASTA 10 MICRAS, OPCIONALMENTE JUNTO CON SUSTANCIAS ANTIINFLAMATORIAS, BRONCODILATADORAS, ANTIALERGICAS Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MUSCARINICO M3 UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS
PE2007001164A 2006-08-31 2007-08-28 Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano PE20080985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119883A EP1900737A1 (en) 2006-08-31 2006-08-31 Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Publications (1)

Publication Number Publication Date
PE20080985A1 true PE20080985A1 (es) 2008-09-05

Family

ID=37685707

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001164A PE20080985A1 (es) 2006-08-31 2007-08-28 Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano

Country Status (21)

Country Link
US (1) US20090264461A1 (es)
EP (2) EP1900737A1 (es)
JP (1) JP2010501611A (es)
KR (1) KR20090051110A (es)
CN (1) CN101506205A (es)
AR (1) AR062582A1 (es)
AU (1) AU2007291515A1 (es)
BR (1) BRPI0716205A2 (es)
CA (1) CA2660983A1 (es)
CL (1) CL2007002524A1 (es)
GT (1) GT200900044A (es)
IL (1) IL196808A0 (es)
MA (1) MA31412B1 (es)
MX (1) MX2009002300A (es)
NO (1) NO20091231L (es)
PE (1) PE20080985A1 (es)
RU (1) RU2009111390A (es)
TN (1) TN2009000069A1 (es)
TW (1) TW200817399A (es)
WO (1) WO2008025541A1 (es)
ZA (1) ZA200900449B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
CA2670846C (en) * 2006-11-23 2014-12-23 Ergonex Pharma Gmbh Pharmaceutical compositions for the treatment of capillary arteriopathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.

Also Published As

Publication number Publication date
TN2009000069A1 (en) 2010-08-19
US20090264461A1 (en) 2009-10-22
JP2010501611A (ja) 2010-01-21
CL2007002524A1 (es) 2008-07-11
CA2660983A1 (en) 2008-03-06
KR20090051110A (ko) 2009-05-20
EP2064210A1 (en) 2009-06-03
AU2007291515A1 (en) 2008-03-06
ZA200900449B (en) 2010-01-27
AR062582A1 (es) 2008-11-19
CN101506205A (zh) 2009-08-12
GT200900044A (es) 2012-01-16
MA31412B1 (fr) 2010-06-01
RU2009111390A (ru) 2010-10-10
TW200817399A (en) 2008-04-16
IL196808A0 (en) 2009-11-18
BRPI0716205A2 (pt) 2013-11-12
EP1900737A1 (en) 2008-03-19
NO20091231L (no) 2009-03-25
WO2008025541A1 (en) 2008-03-06
MX2009002300A (es) 2009-03-20

Similar Documents

Publication Publication Date Title
ES2280538T3 (es) Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia.
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
PE20080924A1 (es) Medicamento que comprende, por separado o juntos, una sal de glicopirronio, un agonista del adreno-receptor beta-2 y un corticosteroide
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
HUP0301203A2 (hu) Szkopin- és tropenolszármazékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra
CO6270364A2 (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos de proliferacion celular
GT200600471A (es) Antagonistas del receptor 3 de la histamina
JP2008519794A5 (es)
KR20170042595A (ko) 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
IL171591A (en) Quinuclidine derivatives, process for their preparation and use thereof for the manufacture of medicaments for the treatment of conditions mediated by the muscarinic m3 receptor
UA92490C2 (en) Imidazoquinolines as lipid kinase inhibitors
CL2008001345A1 (es) Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras.
TW200813045A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CN104520291A (zh) 用于调节egfr活性的化合物和组合物
JP2012504560A5 (es)
GB2468073A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
UY37328A (es) Compuestos diazaheterobicíclicos sustituidos y su uso
BRPI0816219B8 (pt) compostos contendo guanidina úteis como antagonistas de receptor muscarínico, composição farmacêutica e uso
HRP20151338T1 (hr) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
MX2010012189A (es) Derivados de quinuclidina como antagonistas del receptor m3 muscarinico.
CR20120197A (es) Polipéptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
WO2008099186A8 (en) Heterocyclic derivatives as m3 muscarinic receptors
PE20080985A1 (es) Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano

Legal Events

Date Code Title Description
FC Refusal